SCHEMBL19477147

SCHEMBL19477147

CNC[C@@H](O)COc1cc(Nc2nccc(NC)n2)ccc1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 8/20 0.48
CDK2 P24941 7/20 0.47
CDK4 P11802 6/20 0.47
AURKA O14965 3/20 0.46
AURKB Q96GD4 3/20 0.46
MAPK1 P28482 2/20 0.46
PLK4 O00444 1/20 0.46
CHEK1 O14757 1/20 0.46
PDPK1 O15530 1/20 0.46
DAPK3 O43293 1/20 0.46
ROCK2 O75116 1/20 0.46
CHEK2 O96017 1/20 0.46
CDK1 P06493 1/20 0.46
CSF1R P07333 1/20 0.46
PIM1 P11309 1/20 0.46
FGFR1 P11362 1/20 0.46
FLT1 P17948 1/20 0.46
FGFR3 P22607 1/20 0.46
RPS6KB1 P23443 1/20 0.46
MARK3 P27448 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25610232 0.90 IGF1R (0.48) IGF1RCDK2CDK4AURKAAURKB
SCHEMBL19477142 0.90 IGF1R (0.48) IGF1RCDK2CDK4AURKAAURKB
SCHEMBL19477149 0.90 IGF1R (0.48) IGF1RCDK2CDK4AURKAAURKB
SCHEMBL19700678 0.88 AURKA (0.49) IGF1RCDK2CDK4AURKAAURKB
SCHEMBL19476818 0.88 AURKA (0.49) IGF1RCDK2CDK4AURKAAURKB
SCHEMBL19476830 0.88 AURKA (0.49) IGF1RCDK2CDK4AURKAAURKB
SCHEMBL23588539 0.87 CDK2 (0.44) IGF1RCDK2CDK4AURKAMAPK1
SCHEMBL19477507 0.84 EHMT2 (0.54) IGF1RCDK2CDK4AURKAAURKB
SCHEMBL19477070 0.84 EHMT2 (0.54) IGF1RCDK2CDK4AURKAAURKB
SCHEMBL19477068 0.84 EHMT2 (0.54) IGF1RCDK2CDK4AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442947-B1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS EPIZYME INC (US) 2023-06-07 EP disclosed
US-20210213014-A1 METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES Epizyme, Inc. 2021-07-15 US disclosed
US-20210198277-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS Epizyme, Inc. 2021-07-01 US disclosed
US-20170355712-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS Epizyme, Inc. 2017-12-14 US disclosed
US-20170355712-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS Epizyme, Inc. 2017-12-14 US disclosed
WO-2017181177-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS Epizyme, Inc. (US) 2017-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355712-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS SHMT1, BHMT, BHMT2 IGF1R 4094/4885CDK2 1058/4885CDK4 2646/4885
US-20210198277-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS SHMT1, BHMT, BHMT2 IGF1R 4094/4885CDK2 1058/4885CDK4 2646/4885
US-20210213014-A1 METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES EHMT2, BHMT2, BHMT IGF1R 4311/4885CDK2 3088/4885CDK4 4318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.